A multi-center, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of E2007 (perampanel) in patients with painful diabetic neuropathy (PDN) or post-herpetic neuralgia (PHN).

Trial Profile

A multi-center, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of E2007 (perampanel) in patients with painful diabetic neuropathy (PDN) or post-herpetic neuralgia (PHN).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Perampanel (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 15 Mar 2012 This trial is recruiting in Hungary and England.
    • 15 Mar 2012 Additional locations (England, Germany, Hungary, Lithuania) added as reported by European Clinical Trials Database.
    • 06 Mar 2012 Actual patient number is 262 and company (Eisai Inc) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top